Literature DB >> 32118562

Hindsight is 20/20.

Alexander T Moffett1, Harry Hollander2, Gail Berkenblit1, Justin C McArthur3, Reza Manesh1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32118562      PMCID： PMC7850635          DOI： 10.12788/jhm.3358

Source DB:  PubMed          Journal:  J Hosp Med        ISSN： 1553-5592            Impact factor:   2.960


× No keyword cloud information.
  15 in total

1.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 2.  Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Authors:  Mark S Freedman; Giancarlo Comi; Nicola De Stefano; Frederik Barkhof; Chris H Polman; Bernard M J Uitdehaag; Lorenz Lehr; Bettina Stubinski; Ludwig Kappos
Journal:  Mult Scler Relat Disord       Date:  2013-07-31       Impact factor: 4.339

3.  Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event.

Authors:  O Gout; C Lebrun-Frenay; P Labauge; G E Le Page; P Clavelou; S Allouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-11-19       Impact factor: 10.154

Review 4.  Evolving concepts in the treatment of relapsing multiple sclerosis.

Authors:  Giancarlo Comi; Marta Radaelli; Per Soelberg Sørensen
Journal:  Lancet       Date:  2016-11-24       Impact factor: 79.321

5.  Does natalizumab therapy worsen neuromyelitis optica?

Authors:  Anu Jacob; Michael Hutchinson; Liene Elsone; Siobhan Kelly; Rehiana Ali; Ivars Saukans; Niall Tubridy; Mike Boggild
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 6.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

7.  The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Authors:  Andrew J Solomon; Dennis N Bourdette; Anne H Cross; Angela Applebee; Philip M Skidd; Diantha B Howard; Rebecca I Spain; Michelle H Cameron; Edward Kim; Michele K Mass; Vijayshree Yadav; Ruth H Whitham; Erin E Longbrake; Robert T Naismith; Gregory F Wu; Becky J Parks; Dean M Wingerchuk; Brian L Rabin; Michel Toledano; W Oliver Tobin; Orhun H Kantarci; Jonathan L Carter; B Mark Keegan; Brian G Weinshenker
Journal:  Neurology       Date:  2016-08-31       Impact factor: 9.910

Review 8.  Multiple sclerosis.

Authors:  Alan J Thompson; Sergio E Baranzini; Jeroen Geurts; Bernhard Hemmer; Olga Ciccarelli
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

9.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.

Authors:  Katharine Harding; Owain Williams; Mark Willis; James Hrastelj; Anthony Rimmer; Fady Joseph; Valentina Tomassini; Mark Wardle; Trevor Pickersgill; Neil Robertson; Emma Tallantyre
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

10.  Comorbidity delays diagnosis and increases disability at diagnosis in MS.

Authors:  R A Marrie; R Horwitz; G Cutter; T Tyry; D Campagnolo; T Vollmer
Journal:  Neurology       Date:  2008-10-29       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.